{"id":"W2346455687","doi":"10.6000/1927-7229.2015.04.03.1","title":"Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors","year":2015,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Progression-free survival; Performance status; Erlotinib Hydrochloride; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007713285,0.000204902,0.0005789624,0.0001746467,0.0001159181,0.0003847675,0.0001746272,0.0002896492,0.0005392519],"category_scores_gemma":[0.0007810277,0.00005016879,0.0003427202,0.0002150628,0.0001028259,0.0001618583,0.0001264015,0.0002480834,0.0001456528],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003916499,"about_ca_system_score_gemma":0.0005112257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003390218,"about_ca_topic_score_gemma":0.0008536547,"domain_scores_codex":[0.9996468,0.0001432515,0.0000291053,0.00006631495,0.00007795895,0.00003661955],"domain_scores_gemma":[0.9995385,0.0001182226,0.0001994382,0.00002703376,0.00004791499,0.00006887931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02775704,0.002280057,0.6866501,0.001213596,0.001229429,0.002160984,0.0002245623,0.002110967,0.02858403,0.0001095014,0.002011909,0.2456678],"study_design_scores_gemma":[0.004503774,0.04709388,0.9142615,0.0001662951,0.0008186586,0.008225814,0.0002675021,0.003076242,0.01099128,0.0001317446,0.01043758,0.00002570096],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916705,0.007083564,0.0002572346,0.0001367802,0.00002728917,0.00005384968,0.000153467,0.0000114125,0.0006059725],"genre_scores_gemma":[0.9976975,0.001298099,0.000210021,0.0001395252,0.00004986106,0.00002788086,0.0003642309,0.000002184466,0.0002107948],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007713285,"threshold_uncertainty_score":0.004079223,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02052507521711275,"score_gpt":0.3760198581670536,"score_spread":0.3554947829499409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}